Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues

Autor: Andrea Vallés‐Martí, Richard R. deGoeij‐de Haas, Alex A. Henneman, Sander R. Piersma, Thang V. Pham, Jaco C. Knol, Joanne Verheij, Frederike Dijk, Hans Halfwerk, Elisa Giovannetti, Connie R. Jiménez, Maarten F. Bijlsma

Publikováno v: Molecular Oncology, Vol 18, Iss 8, Pp 2020-2041 (2024)

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a limited number of known driver mutations but considerable cancer cell heterogeneity. Phosphoproteomics provides a direct read‐out of aberrant signaling and the resultant clinic

Externí odkaz: https://doaj.org/article/e8ff82023c7546bf9b7c1d4e26f666f5

Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma

Autor: Vallés-Martí, Andrea, Mantini, Giulia, Manoukian, Paul, Waasdorp, Cynthia, Sarasqueta, Arantza Fariña, de Goeij-de Haas, Richard R., Henneman, Alex A., Piersma, Sander R., Pham, Thang V., Knol, Jaco C., Giovannetti, Elisa, Bijlsma, Maarten F., Jiménez, Connie R.

Publikováno v: In Cell Reports 27 June 2023 42(6)

Blood‐circulating EV‐miRNAs, serum TARC, and quantitative FDG‐PET features in classical Hodgkin lymphoma

Autor: Esther E. E. Drees, Julia Driessen, Gerben J. C. Zwezerijnen, Sandra A. W. M. Verkuijlen, Jakoba J. Eertink, Monique A. J. vanEijndhoven, Nils J. Groenewegen, Andrea Vallés‐Martí, Daphne deJong, Ronald Boellaard, Henrica C. W. deVet, Dirk M. Pegtel, Josée M. Zijlstra

Publikováno v: eJHaem, Vol 3, Iss 3, Pp 908-912 (2022)

Abstract Blood‐based biomarkers are gaining interest for response evaluation in classical Hodgkin lymphoma (cHL). However, it is unknown how blood‐based biomarkers relate to quantitative 18F‐FDG‐PET features. We correlated extracellular vesic

Externí odkaz: https://doaj.org/article/8a2200b23a984d21aa0f98dc54ac8e5b

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer

Autor: Connie R. Jimenez, Franziska Böttger, Andrea Vallés-Martí, Loraine Cahn

Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-44 (2021)
Journal of Experimental & Clinical Cancer Research : CR
Böttger, F, Vallés, AV, Cahn, L & Jimenez, C R 2021, ' High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer ', JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 40, no. 1, pp. 343 . https://doi.org/10.1186/s13046-021-02134-y

Mounting evidence indicates that vitamin C has the potential to be a potent anti-cancer agent when administered intravenously and in high doses (high-dose IVC). Early phase clinical trials have confirmed safety and indicated efficacy of IVC in eradic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88090b67afa9ac1a53ac94db11de2e26
https://doaj.org/article/382bf00c77f64c89bc652c2e4ca8c0ae